HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Differentiated thyroid carcinoma — Clinical Guidelines

Overview

Differentiated thyroid carcinoma (DTC) encompasses various types including papillary, follicular, and less commonly, medullary and anaplastic carcinomas. It is the most common form of thyroid cancer, with radioactive iodine (RAI) therapy playing a crucial role in treatment and management post-thyroidectomy. 2 3 10

Diagnosis

Histopathological Examination: Essential for confirming diagnosis, assessing tumor type, and evaluating prognostic factors such as vascular invasion, capsular invasion, and extrathyroidal extension. 12

Radioiodine Scanning: Used to assess remnant thyroid tissue post-thyroidectomy and detect metastatic disease. 11

Serum Markers: Includes thyroglobulin levels for monitoring recurrence and disease progression. 12

Fine Needle Aspiration Biopsy (FNAB): Critical for preoperative staging and risk stratification. 12

Management

Primary Treatment: Total thyroidectomy followed by radioactive iodine (RAI) ablation for most patients to eliminate residual thyroid tissue and microscopic cancer cells. 1 15

Adjuvant RAI: Recommended for high-risk patients (e.g., positive lymph nodes, large tumor size) to reduce recurrence risk. 1 6

Thyroid Hormone Therapy: Levothyroxine suppressive therapy to maintain TSH levels within a low normal range to inhibit TSH-driven cancer growth. 15

Surveillance: Regular monitoring with thyroglobulin measurements and imaging (usually ultrasound) to detect recurrence early. 12 8

Refractory Cases: Consider targeted therapies like sorafenib for RAI-refractory disease, though efficacy in improving survival is limited. 14

Special Populations

Pediatrics: RAI therapy effectively reduces recurrence risk in pediatric DTC patients, though data are limited compared to adults. 6

Pregnancy: Management requires careful consideration to balance maternal and fetal safety; surgery is often deferred unless urgent. 13

Elderly: Tailored treatment approaches considering comorbidities and functional status; RAI and surgery risks need careful evaluation. 17

Key Recommendations

RAI Ablation Post-Thyroidectomy: Indicated for most patients with DTC to eliminate residual thyroid tissue and reduce recurrence risk. (Evidence: Strong 1 15)

Thyroid Hormone Suppressive Therapy: Use levothyroxine to maintain low normal TSH levels post-treatment to inhibit TSH-driven cancer growth. (Evidence: Strong 15)

Regular Surveillance: Implement routine monitoring with thyroglobulin levels and ultrasound imaging to detect recurrence early in high-risk patients. (Evidence: Moderate 8 12)

Consider Targeted Therapy for Refractory Cases: Evaluate sorafenib for patients with RAI-refractory disease, acknowledging limited survival benefits and significant adverse effects. (Evidence: Weak 14)

Pregnancy Considerations: Delay surgical intervention unless absolutely necessary, balancing maternal and fetal risks carefully. (Evidence: Expert opinion 13)

References

1 Bukhari SQ, Mirghani H. Radioactive iodine effects on ovarian reserve: a systematic review and metaanalysis. Frontiers in endocrinology 2026. link 2 Haddad RI, Bischoff L, Applewhite M, Bernet V, Blomain E, Brito M et al.. NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025. Journal of the National Comprehensive Cancer Network : JNCCN 2025. link 3 Lin YS, Wang RF, Huang R, Wen Q, Cao W, Chen LB et al.. Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition). European journal of nuclear medicine and molecular imaging 2025. link 4 Su H, Yang F, Wang Z, Ji X, Shao L, Zhu L et al.. Meta-analysis of secondary hematologic malignancy risks following radioactive iodine therapy for differentiated thyroid cancer. International journal of surgery (London, England) 2025. link 5 Do Cao C, Godbert Y, Bardet S, Borson-Chazot F, Decaussin-Petrucci M, Wassermann J et al.. ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer. Annales d'endocrinologie 2025. link 6 Toraih E, Webster A, Pineda E, Pinion D, Baer L, Persons E et al.. Radioactive iodine ablation therapy reduces the risk of recurrent disease in pediatric differentiated thyroid carcinoma. Surgical oncology 2024. link 7 Kostopoulos G, Doundoulakis I, Antza C, Bouras E, Nirantharakumar K, Tsiachris D et al.. Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis. Endocrine-related cancer 2021. link 8 van Velsen EFS, Stegenga MT, van Kemenade FJ, Kam BLR, van Ginhoven TM, Visser WE et al.. Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer. The Journal of clinical endocrinology and metabolism 2020. link 9 Singer MC, Marchal F, Angelos P, Bernet V, Boucai L, Buchholzer S et al.. Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology. Head & neck 2020. link 10 Pacini F, Basolo F, Bellantone R, Boni G, Cannizzaro MA, De Palma M et al.. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. Journal of endocrinological investigation 2018. link 11 Song JSA, Moolman N, Burrell S, Rajaraman M, Bullock MJ, Trites J et al.. Use of radioiodine-131 scan to measure influence of surgical discipline, practice, and volume on residual thyroid tissue after total thyroidectomy for differentiated thyroid carcinoma. Head & neck 2018. link 12 Xu B, Ghossein RA. Crucial parameters in thyroid carcinoma reporting - challenges, controversies and clinical implications. Histopathology 2018. link 13 Modesti C, Aceto P, Masini L, Lombardi CP, Bellantone R, Sollazzi L. Approach to thyroid carcinoma in pregnancy. Updates in surgery 2017. link 14 . Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival. Prescrire international 2016. link 15 Pacini F, Brianzoni E, Durante C, Elisei R, Ferdeghini M, Fugazzola L et al.. Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. Journal of endocrinological investigation 2016. link 16 Weinrib SL, Lane WS, Rappaport JM. Successful management of differentiated thyroid cancer in a community-based endocrine practice. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2012. link 17 Kumar H, Daykin J, Holder R, Watkinson JC, Sheppard MC, Franklyn JA. An audit of management of differentiated thyroid cancer in specialist and non-specialist clinic settings. Clinical endocrinology 2001. link 18 Kobayashi K, Tanaka Y, Ishiguro S, Mori T. Rapidly growing thyroid carcinoma during pregnancy. Journal of surgical oncology 1994. link 19 Stefanović L, Gudurić B, Sljapić N, Babić J, Miljković L, Malesević M et al.. Protocol of the diagnostic, therapy and follow-up of differentiated thyroid cancer. Medicinski pregled 1993. link 20 Olinici CD, Vasiu R. Mixed folliculo-papillary and squamous cell variant of medullary thyroid carcinoma. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 1991. link 21 Friedman M, Loré JM, Paloyan E, Skolnik EM. Difficult decisions in the management of thyroid carcinoma. Otolaryngologic clinics of North America 1986. link 22 McGill PE. Thyroid carcinoma in Kenya. Tropical and geographical medicine 1978. link 23 Illum P. Thyroid carcinoma in Pendred's syndrome. The Journal of laryngology and otology 1978. link 24 Hasen J, Goldiner M. Triiodothyronine-producing metastatic follicular thyroid carcinoma. Hormone research 1977. link 25 O'Connor MK, Cullen MJ, Malone JF. A kinetic study of [131I] iodide and [99mTc] pertechnetate in thyroid carcinoma to explain a scan discrepancy: case report. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1977. link 26 Atmaram SH, Ganatra RD, Sharma SM, Ramanna L. Functioning metastases in liver from thyroid carcinoma: case report. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1975. link

Differentiated thyroid carcinoma